2018 NIH Alzheimer's Research Summit

All Day
on Thursday, March 1, 2018
Natcher Auditorium, NIH campus, in Bethesda, Maryland.
The NIH AD Research Summits are key strategic planning meetings tied to the implementation of the first goal of the National Plan to Address Alzheimer’s: to treat and prevent Alzheimer's disease by 2025. They bring together a multi-stakeholder community including government, industry, academia, private foundations, and patient advocates to formulate an integrated, translational research agenda that will enable the development of effective therapies (disease modifying and palliative) across the disease continuum for the cognitive as well as neuropsychiatric symptoms of Alzheimer’s disease. The 2012 and 2015 AD Research Summits delivered recommendations that served as the basis for developing research implementation milestones detailing specific steps and success criteria for the NIH and other stakeholders towards the development of effective treatment and prevention for AD. The milestones span the entire AD research landscape including basic, translational, clinical and health services research and serve as the basis for the development of the NIH Alzheimer's Disease Bypass Budget. Goal: The 2018 Summit will build on the foundation laid by the NIH AD Research Summits held in 2012 and 2015. It will feature progress towards achieving the AD research implementation milestones and to continue the development of an integrated multidisciplinary research agenda necessary to enable precision medicine for AD. Key to achieving this goal is the identification of: 1) resources/infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and 2) strategies to engage patients, caregivers, and citizens as direct partners in research. Program Structure: The central programmatic themes of the 2018 Summit are: 1) understanding disease heterogeneity, 2) enhancing research rigor, reproducibility, and translatability and 3) enabling rapid translational learning through open science systems and incentives. The Program agenda will be organized around seven sessions: Novel Mechanistic Insights into the Complex Biology and Heterogeneity of AD Enabling Precision Medicine for AD Translational Tools and Infrastructure to Enable Predictive Drug Development Emerging Therapeutics Understanding the Impact of the Environment to Advance Disease Prevention Advances in Disease Monitoring, Assessment and Care Building an Open Science Research Ecosystem to Accelerate AD Therapy Development The program will begin with an overview of progress achieved to date, followed by three plenary lectures. Each of the seven sessions will feature up to four brief presentations followed by a moderated discussion that will include 6-9 panelists with diverse expertise. Collectively, the session speakers and panelists will highlight major advances and discuss key issues. The composition of speakers and panelists for each session will include representatives from academia, industry, federal agencies, private foundations and public advocacy groups working on Alzheimer’s and other complex diseases. Outcome: The general program will be followed by a writing session during which a select group of experts together with NIA/NIH staff and representatives from other U.S. AD funding agencies and NAPA Council members will discuss and help finalize the recommendations put forward by the Summit participants. These recommendations will inform research priorities and serve as the basis for updating and refining the NAPA research milestones for measuring progress towards the goal to prevent or treat AD by 2025.